Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Phase 1

Recruiting

Conditions: Sequestra
Depression

Interventions: Behavioral: GCBT
Drug: Aripiprazole
Drug: Lithium Carbonate
Drug: Fluoxetine
Drug: Sertraline
Drug: Vortioxetine
Drug: Duloxetine
Drug: Olanzapine

First Posted Date: 2023-04-18

Last Posted Date: 2023-08-14

Lead Sponsor: First Affiliated Hospital of Chongqing Medical University

Target Recruit Count: 520

Registration Number: NCT05814640

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China

A Study of Olanzapine in Patients With Acute Agitation

Phase 3

Not yet recruiting

Conditions: Acute Agitation

Interventions: Drug: Olanzapine
Drug: Haloperidol

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 318

Registration Number: NCT05803642

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Phase 2

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Advanced Biliary Tract Carcinoma
Advanced Esophageal Carcinoma
Metastatic Esophageal Carcinoma
Locally Advanced Biliary Tract Carcinoma
Locally Advanced Colorectal Carcinoma
Locally Advanced Esophageal Carcinoma
Locally Advanced Gastric Carcinoma
Metastatic Colorectal Carcinoma (mCRC)
Advanced Lung Carcinoma

Interventions: Drug: Olanzapine
Drug: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2023-01-30

Last Posted Date: 2025-04-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 66

Registration Number: NCT05705492

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge from Ambulatory Surgery

Phase 2

Recruiting

Conditions: Postoperative Nausea and Vomiting

Interventions: Drug: Olanzapine
Drug: Placebo

First Posted Date: 2023-01-09

Last Posted Date: 2024-10-08

Lead Sponsor: Yale University

Target Recruit Count: 455

Registration Number: NCT05676294

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Phase 3

Not yet recruiting

Conditions: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics

Interventions: Drug: olanzapine
Drug: Empagliflozin

First Posted Date: 2023-01-03

Last Posted Date: 2023-01-25

Lead Sponsor: Tanta University

Target Recruit Count: 40

Registration Number: NCT05669742

Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery

Not Applicable

Recruiting

Conditions: Coronary Artery Disease
Aortic Valve Disease

Interventions: Drug: Olanzapine 10 MG
Drug: Placebo capsule
Procedure: Flow-targeted hemodynamic management
Procedure: Pressure-targeted hemodynamic management
Procedure: Low tidal-volume ventilation
Drug: Dexamethasone phosphate
Drug: Isotonic sodium chloride (0.9%)
Procedure: No ventilation